Pfizer Taps Into 'Doggybone DNA' For mRNA Vaccines, Gene Therapy Production

Targets Manufacturing Bottleneck

 
• By Andrew McConaghie

New enzyme-based approach could help make DNA-based therapy manufacturing faster, more scaleable and more reliable.

Pfizer
The deal allows Pfizer to manufacture 'doggybone DNA' in its own facilities, but further details have not been disclosed. • Source: Shutterstock

More from Business

More from Scrip